Analytical Ultracentrifugation to Assess the Quality of LNP-mRNA Therapeutics

Int J Mol Sci. 2024 May 24;25(11):5718. doi: 10.3390/ijms25115718.

Abstract

The approval of safe and effective LNP-mRNA vaccines during the SARS-CoV-2 pandemic is catalyzing the development of the next generation of mRNA therapeutics. Proper characterization methods are crucial for assessing the quality and efficacy of these complex formulations. Here, we show that analytical ultracentrifugation (AUC) can measure, simultaneously and without any sample preparation step, the sedimentation coefficients of both the LNP-mRNA formulation and the mRNA molecules. This allows measuring several quality attributes, such as particle size distribution, encapsulation efficiency and density of the formulation. The technique can also be applied to study the stability of the formulation under stress conditions and different buffers.

Keywords: LNP-mRNA; analytical ultracentrifugation (AUC); free RNA; quality; therapeutics; vaccine.

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / virology
  • Humans
  • Nanoparticles / chemistry
  • Particle Size
  • RNA, Messenger* / genetics
  • SARS-CoV-2* / genetics
  • Ultracentrifugation* / methods

Substances

  • RNA, Messenger
  • COVID-19 Vaccines

Grants and funding

This study was supported by the EU Joint Research Centre by the EU Joint Research Centre Exploratory Research programme ‘FUTURE’ and through the work programme “Preparedness And Innovation To Tackle Health Challenges” (32401-PITCH) and within the Portfolio “Better Preparedness and Response To Health Crises” (27-BREATH).